Masimo sues US Customs over approval of Apple Watch imports

Medical technology company Masimo has sued U.S. Customs and Border Protection (CBP), alleging the agency improperly reversed its decision to allow Apple to import Apple Watches with blood-oxygen technology, despite an existing ITC import ban based on Masimo's patent infringement claims. Masimo argues CBP's move creates an unlawful loophole, undermining the ITC's exclusion order and escalating the contentious intellectual property dispute that could impact Apple's ability to sell full-featured smartwatches in the U.S.

Analysis

Masimo Corporation (MASI) has escalated its intellectual property dispute with Apple Inc. (AAPL) by filing a lawsuit against U.S. Customs and Border Protection (CBP). The legal action challenges a recent CBP decision that permits the importation of Apple Watches equipped with blood-oxygen sensing technology, a feature previously blocked by a U.S. International Trade Commission (ITC) exclusion order in 2023 following a patent infringement ruling in Masimo's favor. Masimo contends that CBP's reversal, allegedly made without justification or notification, creates a loophole that nullifies the ITC's enforcement power. The market's reaction to this development is notably divergent, with per-ticker sentiment for Masimo being strongly negative (-0.6) while Apple's is strongly positive (+0.6). This suggests that investors perceive CBP's ruling as a significant commercial victory for Apple, mitigating a key product risk, while viewing Masimo's lawsuit against a federal agency as a costly and uncertain endeavor. The legal focus now shifts from a direct corporate patent battle to a complex challenge of regulatory procedure, with the outcome determining Apple's ability to sell its full-featured smartwatches in the U.S.

Key Decisions for Investors

• Investors in Apple (AAPL) should view the CBP's favorable ruling as a significant de-risking event for the wearables segment, however, the new litigation represents a key risk to monitor as an adverse court ruling could reinstate the import ban.
• For Masimo (MASI) investors, the strongly negative market sentiment suggests this lawsuit against a government agency is perceived as a high-risk, high-cost strategy, and its potential success must be weighed against the ongoing legal expenses and the challenge of overturning a federal agency's decision.
• The sharp divergence in sentiment between AAPL and MASI indicates the market has priced in a higher probability of success for Apple; traders could monitor the initial court proceedings on Masimo's request for a halt as a key catalyst that could rapidly alter the outlook for both companies.